The next step of the therapy proposed by the KDIGO guidelines is GLP1-RAs and non-steroidal mineralocorticoid receptor antagonists (NS-MRAs).50–52 However, in pivotal studies for GLP1-RAs, baseline albuminuria levels were not specified, although a trial testing semaglutide did not exclude normoalbuminuric patients.53 GLP1-RAs in patients with T2DM and CKD are safe and well tolerated, and significantly improve cardiovascular and renal variables.50 On the other hand, in NS-MRA studies, there were no patients with NA-DKD;49 thus, current recommendations are unavailable for these patients. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.